Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.852
AS - Asia 6.024
EU - Europa 3.826
SA - Sud America 948
AF - Africa 135
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 20.800
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.647
SG - Singapore 2.348
HK - Hong Kong 1.151
CN - Cina 1.082
RU - Federazione Russa 820
BR - Brasile 700
IE - Irlanda 614
IT - Italia 584
VN - Vietnam 529
DE - Germania 491
SE - Svezia 461
IN - India 198
GB - Regno Unito 178
FR - Francia 175
CA - Canada 138
UA - Ucraina 122
BD - Bangladesh 107
FI - Finlandia 95
AR - Argentina 93
TR - Turchia 76
AT - Austria 75
IQ - Iraq 74
ID - Indonesia 73
PK - Pakistan 60
JP - Giappone 58
SA - Arabia Saudita 45
MX - Messico 41
PH - Filippine 41
DK - Danimarca 39
ZA - Sudafrica 39
CO - Colombia 36
ES - Italia 35
KR - Corea 34
NL - Olanda 33
VE - Venezuela 33
EC - Ecuador 30
PL - Polonia 25
UZ - Uzbekistan 25
BE - Belgio 19
JO - Giordania 17
CL - Cile 14
PY - Paraguay 14
KE - Kenya 12
MA - Marocco 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PE - Perù 11
AU - Australia 10
EG - Egitto 10
DZ - Algeria 8
ET - Etiopia 8
IR - Iran 8
KZ - Kazakistan 8
TN - Tunisia 8
JM - Giamaica 7
LB - Libano 7
TH - Thailandia 7
AZ - Azerbaigian 6
MY - Malesia 6
RO - Romania 6
SN - Senegal 6
AL - Albania 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BO - Bolivia 5
IL - Israele 5
MU - Mauritius 5
PS - Palestinian Territory 5
RS - Serbia 5
AM - Armenia 4
BG - Bulgaria 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
NG - Nigeria 4
PA - Panama 4
TW - Taiwan 4
BY - Bielorussia 3
CI - Costa d'Avorio 3
GA - Gabon 3
GR - Grecia 3
LV - Lettonia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
BH - Bahrain 2
CG - Congo 2
CZ - Repubblica Ceca 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
MD - Moldavia 2
MT - Malta 2
NZ - Nuova Zelanda 2
Totale 20.771
Salva come PNG Salva come JPEG
Città #
Singapore 1.333
Ann Arbor 1.331
Hong Kong 1.114
Ashburn 934
Fairfield 850
Dublin 606
San Jose 591
Woodbridge 481
Wilmington 435
Seattle 389
Chandler 372
Houston 325
Cambridge 320
Frankfurt am Main 296
New York 288
Princeton 248
Chicago 220
Beijing 219
The Dalles 216
Jacksonville 167
Santa Clara 158
Ho Chi Minh City 156
Los Angeles 140
Shanghai 136
Hanoi 124
Altamura 122
Lauterbourg 119
Lawrence 118
Milan 115
Dallas 96
Moscow 78
San Diego 73
Helsinki 68
Dearborn 63
Council Bluffs 58
São Paulo 56
Toronto 56
Jakarta 51
Vienna 51
Buffalo 45
Andover 44
Guangzhou 39
London 39
Boardman 37
Baghdad 34
Nanjing 33
Tokyo 33
Hefei 32
Rio de Janeiro 30
Salt Lake City 30
Munich 29
Hangzhou 28
Nuremberg 28
Orem 28
Haiphong 26
Pune 26
Turin 26
Dhaka 25
Ottawa 25
Washington 24
Falls Church 23
Dong Ket 22
Lahore 22
Rome 22
Seoul 22
Da Nang 21
Riyadh 21
Tashkent 20
Chennai 19
Brussels 18
Norwalk 18
Johannesburg 17
Tianjin 17
Mumbai 16
San Francisco 16
Amman 15
Atlanta 15
Jinan 15
Phoenix 15
Amsterdam 14
Columbus 14
Tampa 14
Warsaw 14
Boston 13
Brasília 13
Elk Grove Village 13
Hebei 13
Redmond 13
Zhengzhou 13
Brooklyn 12
Guayaquil 12
Istanbul 12
Jeddah 12
Karachi 12
Lachine 12
Montreal 12
Torre Del Greco 12
Changsha 11
Denver 11
Hải Dương 11
Totale 13.851
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 445
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 386
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 379
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 368
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 360
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 340
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 336
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 321
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 304
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 304
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 301
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 288
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 286
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 280
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 267
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 259
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 253
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 235
When progressive dysphagia could be related to an “old friend” – a case report 232
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 224
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 224
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 223
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 221
Novel cytotoxic chemotherapies in small cell lung carcinoma 215
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 213
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 212
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 205
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 194
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 193
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 190
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 189
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 185
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 184
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 181
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 181
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 180
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 180
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 180
Focus on nivolumab in NSCLC 179
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 179
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 177
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 177
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 174
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 172
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 168
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 167
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 166
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 163
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 158
Drugs ten years later: epirubicin 157
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 154
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 153
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 152
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 151
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 149
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 149
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 148
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 148
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 148
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 145
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 145
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 144
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 144
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 142
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 141
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 141
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 141
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 141
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 140
Pilot study with adriamycin and ifosfamide in small cell lung cancer 140
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 138
A new race against lung cancer 136
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 136
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 135
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 134
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 133
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 133
Oxaliplatin doublets in non-small cell lung cancer: A literature review 132
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 131
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 131
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 131
Targeted therapies and immunotherapy in non-small-cell lung cancer 130
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 130
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 130
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 130
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 129
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 127
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 127
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 127
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 127
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 125
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 124
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 124
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 124
Isolated cardiac metastasis from squamous cell esophageal cancer 121
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 121
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity 120
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 119
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 118
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 117
Totale 18.511
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021369 0 0 0 0 0 0 0 0 0 0 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20267.124 783 521 464 642 908 451 1.591 452 710 572 30 0
Totale 21.408